{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T10:01:34Z","timestamp":1785578494691,"version":"3.56.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.taap.2022.115914","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T20:59:06Z","timestamp":1644440346000},"page":"115914","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Occurrence of early afterdepolarization under healthy or hypertrophic cardiomyopathy conditions in the human ventricular endocardial myocyte: In silico study using 109 torsadogenic or non-torsadogenic compounds"],"prefix":"10.1016","volume":"438","author":[{"given":"Bernard","family":"Christophe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2022.115914_bb0005","article-title":"Models of the cardiac L-type calcium current: a quantitative comparison","author":"Agrawal","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.taap.2022.115914_bb0010","series-title":"ICH S7B: the non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals","author":"Anonymous","year":"2005"},{"key":"10.1016\/j.taap.2022.115914_bb0015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.pbiomolbio.2014.08.008","article-title":"EAD and DAD mechanisms analyzed by developing a new human ventricular cell model","volume":"116","author":"Asakura","year":"2014","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"10.1016\/j.taap.2022.115914_bb0020","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/bjp.2008.279","article-title":"International Life Sciences Institute (Health and Environmental Sciences Institute, HESI) initiative on moving towards better predictors of drug-induced torsades de pointes","volume":"154","author":"Bass","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.taap.2022.115914_bb0025","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ymeth.2020.01.010","article-title":"Multi-scale approaches for the simulation of cardiac electrophysiology: II \u2013 tissue-level structure and function","volume":"185","author":"Benson","year":"2021","journal-title":"Methods"},{"key":"10.1016\/j.taap.2022.115914_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.598549","article-title":"Inflammation as a risk factor in cardiotoxicity: an important consideration for screening during drug development","volume":"12","author":"Campana","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.taap.2022.115914_bb0035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.vascn.2016.05.012","article-title":"Comprehensive in vitro Proarrhythmia Assay (CiPA): pending issues for successful validation and implementation","volume":"81","author":"Cavero","year":"2016","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.taap.2022.115914_bb0040","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3389\/fphys.2017.00917","article-title":"Uncertainty quantification reveals the importance of data variability and experimental design considerations for in silico proarrhythmia risk assessment","volume":"8","author":"Chang","year":"2017","journal-title":"Front. Physiol."},{"key":"10.1016\/j.taap.2022.115914_bb0045","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/S1734-1140(13)71486-5","article-title":"Simulation of early after-depolarisation in non-failing human ventricular myocytes: can this help cardiac safety pharmacology?","volume":"65","author":"Christophe","year":"2013","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.taap.2022.115914_bb0050","doi-asserted-by":"crossref","first-page":"88","DOI":"10.9734\/BJPR\/2015\/17850","article-title":"In silico study of transmural dispersion of repolarisation in non-failing human ventricular myocytes : contribution to cardiac safety pharmacology","volume":"7","author":"Christophe","year":"2015","journal-title":"Br. J. Pharm. Res."},{"key":"10.1016\/j.taap.2022.115914_bb0055","author":"Christophe"},{"key":"10.1016\/j.taap.2022.115914_bb0060","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.vascn.2018.12.004","article-title":"Impact of disease state on arrhythmic event detection by action potential modelling in cardiac safety pharmacology","volume":"96","author":"Christophe","year":"2019","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.taap.2022.115914_bb0065","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymeth.2020.02.011","article-title":"Multi-scale approaches for the simulation of cardiac electrophysiology: I \u2013 sub-cellular and stochastic calcium dynamics from cell to organ","volume":"185","author":"Colman","year":"2021","journal-title":"Methods"},{"key":"10.1016\/j.taap.2022.115914_bb0070","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.3389\/fphys.2018.01391","article-title":"Altered Ca2+ and Na+ homeostasis in human hypertrophic cardiomyopathy: implications for Arrhythmogenesis","volume":"9","author":"Coppini","year":"2018","journal-title":"Front. Physiol."},{"key":"10.1016\/j.taap.2022.115914_bb0075","article-title":"Using cardiac ionic cell models to interpret clinical data","volume":"13","author":"Corrado","year":"2021","journal-title":"WIREs Mech. Dis."},{"key":"10.1016\/j.taap.2022.115914_bb0080","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1476-5381.2009.00487.x","article-title":"The thorough QT\/QTc study 4 years after the implementation of the ICH E14 guidance","volume":"159","author":"Darpo","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.taap.2022.115914_bb0085","article-title":"Use of patient health records to quantify drug-related pro-arrhythmic risk","volume":"1","author":"Davies","year":"2020","journal-title":"Cell Report Medicine"},{"key":"10.1016\/j.taap.2022.115914_bb0090","first-page":"72","article-title":"Tachycardie ventriculaire \u00e0 deux foyers oppos\u00e9s variables","volume":"59","author":"Dessertenne","year":"1966","journal-title":"Arch. Mal. Coeur"},{"key":"10.1016\/j.taap.2022.115914_bb0095","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3389\/fphys.2017.00616","article-title":"Optimization of an in silico cardiac cell model for proarrhythmia risk assessment","volume":"8","author":"Dutta","year":"2017","journal-title":"Front. Physiol."},{"key":"10.1016\/j.taap.2022.115914_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2019.106622","article-title":"Relationship of clinical adverse event reports to models of arrhythmia risk","volume":"100","author":"Ether","year":"2019","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.taap.2022.115914_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1087057115594589","article-title":"A new perspective in the field of cardiac safety testing through the comprehensive in vitro proarrhythmia assay paradigm","volume":"21","author":"Fermini","year":"2016","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.taap.2022.115914_bb0110","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1161\/01.RES.0000016960.61087.86","article-title":"Ionic current basis of electrocardiographic waveforms. A model study","volume":"90","author":"Gima","year":"2002","journal-title":"Circ. Res."},{"key":"10.1016\/j.taap.2022.115914_bb0115","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrd.2015.34","article-title":"Evolution of strategies to improve preclinical cardiac safety testing","volume":"15","author":"Gintant","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.taap.2022.115914_bb0120","article-title":"Electrophysiological and structural remodeling in heart failure modulate Arrhythmogenesis. 1D simulation study","volume":"9","author":"Gomez","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.taap.2022.115914_bb0125","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40264-017-0584-4","article-title":"Drug-induced QT prolongation and Torsades de pointes: an all-exclusive relationship or time for an amicable separation?","volume":"41","author":"Hondeghem","year":"2018","journal-title":"Drug Saf."},{"key":"10.1016\/j.taap.2022.115914_bb0130","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00210-010-0549-y","article-title":"Oscillations of cardiac wave length and proarrhythmia","volume":"382","author":"Hondeghem","year":"2010","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.taap.2022.115914_bb0135","article-title":"Determinants of early afterdepolarization properties in ventricular myocyte models","volume":"14","author":"Huang","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.taap.2022.115914_bb0140","doi-asserted-by":"crossref","DOI":"10.1063\/1.5132618","article-title":"In silico models for evaluating proarrhythmic risk of drugs","volume":"4","author":"Hwang","year":"2020","journal-title":"APL Bioeng."},{"key":"10.1016\/j.taap.2022.115914_bb0145","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1152\/advan.00093.2019","article-title":"Teaching cardiac excitation-contraction coupling using a mathematical computer simulation model of human ventricular myocytes","volume":"44","author":"Jeon","year":"2020","journal-title":"Adv. Physiol. Educ."},{"key":"10.1016\/j.taap.2022.115914_bb0150","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.vascn.2016.08.007","article-title":"Significance of integrated in silico transmural ventricular wedge preparation models of human non-failing and failing hearts for safety evaluation of drug candidates","volume":"83","author":"Kubo","year":"2017","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.taap.2022.115914_bb0155","doi-asserted-by":"crossref","first-page":"H106","DOI":"10.1152\/ajpheart.00115.2016","article-title":"Dynamical mechanisms of phase-2 early afterdepolarizations in human ventricular myocytes: insights from bifurcation analyses of two mathematical models","volume":"312","author":"Kurata","year":"2017","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.taap.2022.115914_bb0160","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.vascn.2005.04.011","article-title":"Nonclinical proarrhythmia models: predicting torsades depointes","volume":"52","author":"Lawrence","year":"2005","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.taap.2022.115914_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2019.106654","article-title":"Improving prediction of torsadogenic risk in the CiPA in silico model by appropriately accounting for clinical exposure","volume":"101","author":"Leishman","year":"2020","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.taap.2022.115914_bb0170","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s00392-008-0741-y","article-title":"Clinical characteristics of patients with drug-induced QT interbal prolongation and torsade de pointes: identification of risk factors","volume":"98","author":"Letsas","year":"2009","journal-title":"Clin. Res. Cardiol."},{"key":"10.1016\/j.taap.2022.115914_bb0175","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.116.004628","article-title":"Improving the In Silico Assessment of Proarrhythmia Risk by Combining hERG (Human Ether-\u00e0-go-go-Related Gene) Channel\u2013Drug Binding Kinetics and Multichannel Pharmacology","volume":"10","author":"Li","year":"2017","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"10.1016\/j.taap.2022.115914_bb0180","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/cpt.1647","article-title":"a. General principles for the validation of Proarrhythmia risk prediction models: an extension of the CiPA in silico strategy","volume":"107","author":"Li","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2022.115914_bb0185","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/cpt.1184","article-title":"Assessment of an in silico mechanistic model for Proarrhythmia risk prediction under the CiPA initiative","volume":"105","author":"Li","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2022.115914_bb0190","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1021\/acs.jcim.0c00201","article-title":"In-silico classifiers for the assessment of drug Proarrhythmicity","volume":"60","author":"Llopis-Lorente","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.taap.2022.115914_bb0195","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.vascn.2005.04.007","article-title":"Choice of cardiac tissue plays an important role in the evaluationof drug-induced prolongation of the QT interval in vitro in rabbit","volume":"52","author":"Lu","year":"2005","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.taap.2022.115914_bb0200","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jelectrocard.2017.08.011","article-title":"Cardiologist\u2019s point of view: novel ECG biomarkers and in silico models for proarrhythmic risk prediction; are we ready?","volume":"50","author":"Mason","year":"2017","journal-title":"J. Electrocardiol."},{"key":"10.1016\/j.taap.2022.115914_bb0205","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1039\/C7TX00141J","article-title":"Early afterdepolarisation tendency as a simulated pro-arrhthymic risk indicator","volume":"6","author":"McMillan","year":"2017","journal-title":"Tox. Res."},{"key":"10.1016\/j.taap.2022.115914_bb0210","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/cvr\/cvr044","article-title":"Simulation of multiple ion channel block provides improved early prediction of compounds\u2019 clinical torsadogenic risk","volume":"91","author":"Mirams","year":"2011","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.taap.2022.115914_bb0215","first-page":"246","article-title":"Prediction of thorough QT study results using action potential simulations based on ion channel screens","volume":"70","author":"Mirams","year":"2014","journal-title":"J. Pharm. Tox. Sci."},{"key":"10.1016\/j.taap.2022.115914_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1002061","article-title":"Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation","volume":"7","author":"O'Hara","year":"2011","journal-title":"PLoS Comput.Biol."},{"key":"10.1016\/j.taap.2022.115914_bb0225","doi-asserted-by":"crossref","first-page":"816","DOI":"10.3389\/fphar.2017.00816","article-title":"Novel two-step classifier for Torsades de pointes risk stratification from direct features","volume":"8","author":"Parikh","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.taap.2022.115914_bb0230","first-page":"12","article-title":"Introduction to in silico model for proarrhythmic risk assessment under the CiPA initiative","volume":"27","author":"Park","year":"2019","journal-title":"Trends Clin. Pharmacol."},{"key":"10.1016\/j.taap.2022.115914_bb0235","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.yjmcc.2015.09.003","article-title":"Mechanisms of pro-arrhythmic abnormalities in ventricular repolarisation and anti-arrhythmic therapies in human hypertrophic cardiomyopathy","volume":"96","author":"Passini","year":"2016","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.taap.2022.115914_bb0240","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3389\/fphys.2017.00668","article-title":"Human in silico drug trials demonstrate higher accuracy than animal models in predicting clinical pro-arrhythmic cardiotoxicity","volume":"8","author":"Passini","year":"2017","journal-title":"Front. Physiol."},{"key":"10.1016\/j.taap.2022.115914_bb0245","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1111\/bph.14786","article-title":"Drug-induced shortening of the electromechanical window is an effective biomarker for in silico prediction of clinical risk of arrhythmias","volume":"176","author":"Passini","year":"2019","journal-title":"Br.J.Pharmacol."},{"key":"10.1016\/j.taap.2022.115914_bb0250","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/cvr\/cvt104","article-title":"Early afterdepolarisation in cardiac myocytes: beyond reduced repolarisation reserve","volume":"99","author":"Qu","year":"2013","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.taap.2022.115914_bb0255","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ahj.2013.11.004","article-title":"Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the cardiac safety research consortium","volume":"167","author":"Sager","year":"2014","journal-title":"Am. Heart J."},{"key":"10.1016\/j.taap.2022.115914_bb0260","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/FJC.0b013e3182597f67","article-title":"Transmural dispersion of repolarization as a preclinical marker of drug-induced proarrhythmia","volume":"60","author":"Said","year":"2012","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.taap.2022.115914_bb0265","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/europace\/eut214","article-title":"Epidemiology of symptomatic drug-induced long QT syndrome and torsade de pointes in Germany","volume":"16","author":"Sarganas","year":"2014","journal-title":"Europace"},{"key":"10.1016\/j.taap.2022.115914_bb0270","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pbiomolbio.2020.02.008","article-title":"Cardiomyocyte calcium handling in health and disease: insights from in vitro and in silico studies","volume":"157","author":"Sutanto","year":"2020","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"10.1016\/j.taap.2022.115914_bb0275","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/1715163516641136","article-title":"Drug-induced QT interval prolongation and torsades de pointes: role of the pharmacist in risk assessment, prevention and management","volume":"149","author":"Tisdale","year":"2016","journal-title":"Can. Pharm. J."},{"key":"10.1016\/j.taap.2022.115914_bb0280","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.48890","article-title":"Development, calibration and validation of a novel human ventricular myocyte model in health disease and drug block","volume":"8","author":"Tomek","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.taap.2022.115914_bb0285","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.yjmcc.2020.04.001","article-title":"Human Purkinje in silico model enables mechanistic investigations into automaticity and pro-arrhythmic abnormalities","volume":"142","author":"Trovato","year":"2020","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.taap.2022.115914_bb0290","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1152\/physrev.00024.2019","article-title":"Cardiac transmembrane ion channels and action potentials: cellular physiology and arrhythmogenic behaviour","volume":"101","author":"Varr\u00f3","year":"2021","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.taap.2022.115914_bb0295","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/j.hrthm.2010.09.017","article-title":"Early afterdepolarisation and cardiac arrhthymias","volume":"7","author":"Weiss","year":"2010","journal-title":"Heart Rhythm."},{"key":"10.1016\/j.taap.2022.115914_bb0300","article-title":"Calibration of ionic and cellular cardiac electrophysiology models","volume":"13","author":"Whittaker","year":"2020","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med."},{"key":"10.1016\/j.taap.2022.115914_bb0305","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.drudis.2016.09.027","article-title":"Am I or am I not proarrhythmic? Comparison of various classifications of drug TdP propensity","volume":"22","author":"Wi\u015bniowska","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.taap.2022.115914_bb0310","author":"Woosley"},{"key":"10.1016\/j.taap.2022.115914_bb0315","author":"Woosley"},{"key":"10.1016\/j.taap.2022.115914_bb0320","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/heart.89.11.1363","article-title":"Drug induced QT prolongation and torsades de pointes","volume":"89","author":"Yap","year":"2003","journal-title":"Heart"},{"key":"10.1016\/j.taap.2022.115914_bb0325","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.3389\/fphar.2019.01643","article-title":"Blinded in silico drug trial reveals the minimum set of ion channels for Torsades de pointes risk assessment","volume":"10","author":"Zhou","year":"2019","journal-title":"Front. Pharmacol."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X2200059X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X2200059X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T20:58:07Z","timestamp":1758574687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X2200059X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":65,"alternative-id":["S0041008X2200059X"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2022.115914","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Occurrence of early afterdepolarization under healthy or hypertrophic cardiomyopathy conditions in the human ventricular endocardial myocyte: In silico study using 109 torsadogenic or non-torsadogenic compounds","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2022.115914","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115914"}}